Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Moleculin Biotech ( (MBRX) ).
Moleculin Biotech, Inc. received a deficiency letter from Nasdaq on June 27, 2025, due to its stock price falling below the $1.00 minimum requirement. However, by December 15, 2025, the company regained compliance as its stock price met the required threshold for 10 consecutive business days, resolving the issue.
The most recent analyst rating on (MBRX) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.
Spark’s Take on MBRX Stock
According to Spark, TipRanks’ AI Analyst, MBRX is a Neutral.
Moleculin Biotech’s stock score reflects a high-risk financial position with no revenue and growing losses typical of early-stage biotech firms. Positive developments in clinical trials and a solid financial runway provide potential upside, but significant risks remain due to financial instability, high trial costs, and future funding needs. Technical indicators suggest bearish momentum, and the valuation is unattractive due to the absence of earnings.
To see Spark’s full report on MBRX stock, click here.
More about Moleculin Biotech
Average Trading Volume: 202,169
Technical Sentiment Signal: Sell
Current Market Cap: $10.29M
See more insights into MBRX stock on TipRanks’ Stock Analysis page.